Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Biodegradable Polymeric Nanosystems for Drug Delivery
share announcement

Biodegradable Polymeric Nanosystems for Drug Delivery

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 25 October 2024 | Viewed by 4476

Special Issue Editors

Dr. Ewa Olȩdzka

E-Mail Website
Guest Editor
Department of Analytical Chemistry and Biomaterials, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland
Interests: nanomaterials; nanomedicine; biomaterials; polymeric drug delivery systems; cancer; nanopharmacy; polymer synthesis and characterization; organometallic catalysts
Special Issues, Collections and Topics in MDPI journals
Dr. Urszula Piotrowska

E-Mail Website
Guest Editor
Department of Analytical Chemistry and Biomaterials, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland
Interests: antimicrobial activity; antimicrobial peptides; antitumor activity; biomaterials; colorectal cancer; drug delivery systems; nanotechnology; targeted therapy

Special Issue Information

Dear Colleagues,

We are delighted to invite you to contribute to a Special Issue of the Pharmaceuticals titled "Biodegradable Polymeric Nanosystems for Drug Delivery".

The scientific community is especially interested in drug delivery systems. The use of biodegradable polymeric biomaterials for controlled drug delivery and cell therapy shows potential as a therapeutic option for improving treatment outcomes and patient compliance in a variety of diseases. Different types of polymer-based systems are constantly being researched for targeted strategies and controlled release of active substances, peptides, proteins, and so on. Biodegradable polymers are the preferred choice for the development of polymeric drug delivery systems owing to their high biocompatibility and degradability, Because of the hydrolysable nature of the polymer backbone, canonical physiological cell activities result in the formation of non-toxic natural products that are easily eliminated. Biodegradable polymers can be derived from both natural and synthetic sources, allowing for the selection of appropriate polymeric materials based on the chemical nature of drugs and their application. The size of polymers can vary depending on the drug-loading approach and the biological target, allowing for faster clearance after intravenous administration, prolonged circulation half-life, and increased probability of crossing various biological barriers and preventing accumulation in capillaries and/or other organs. Given the subcellular size of systems, the use of biodegradable polymers modulates the pharmacokinetic properties of various active substances. Polymer vectors can be developed with various molecular organizations and macromolecular structures.

Apart from designing and characterization of micro- and nanoparticles, dendrimers, composites, prodrugs, polymer-drug conjugates, thermosensitive and pH-sensitive polymers, hydrogels, and so on, we intend to include novel techniques used for different drugs delivery based on biodegradable polymers. Furthermore, methods of these systems’ preparation, surface modification and characterization methods as well as drug loading and drug release will be addressed in the proposed Special Issue.

In vivo experiments involving innovative biodegradable nanoparticles for drug delivery will also be accepted.

Authors are kindly invited to submit original papers, communications, and reviews.

We look forward to receiving your contributions.

Dr. Ewa Olȩdzka
Dr. Urszula Piotrowska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 4198 KiB  
Article
Freeze-Dried Camelina Lipid Droplets Loaded with Human Basic Fibroblast Growth Factor-2 Formulation for Transdermal Delivery: Breaking through the Cuticle Barrier to Accelerate Deep Second-Degree Burn Healing
by Hongtao Gao, Xue Wang, Hao Wu, Yuan Zhang, Wenxiao Zhang, Zuobin Wang, Xin Liu, Xiaokun Li and Haiyan Li
Pharmaceuticals 2023, 16(10), 1492; https://doi.org/10.3390/ph16101492 - 20 Oct 2023
Cited by 1 | Viewed by 951
Abstract
Transdermal administration of chemo therapeutics into burn healing may be an effective treatment to reduce toxic side effects and improve patient compliance for burns. As a transdermal delivery system, Camelina lipid droplets (CLDs) have received great attention due to their biocompatibility, high drug [...] Read more.
Transdermal administration of chemo therapeutics into burn healing may be an effective treatment to reduce toxic side effects and improve patient compliance for burns. As a transdermal delivery system, Camelina lipid droplets (CLDs) have received great attention due to their biocompatibility, high drug payload, and rapid absorption. However, the absorbed-related mechanisms of Camelina lipid droplets have not yet been reported. Thus, this paper not only demonstrated that CLD can accelerate skin burn healing through promoting hFGF2 absorption, but also elucidated the mechanism between the skin tissue and keratinocytes using Franz, HE staining, DSC, FTIR spectroscopy, and atomic force microscopy with the presence of CLD-hFGF2 freeze-dried powder. We found that the cumulative release rate of CLD-hFGF2 freeze-dried powder was significantly higher than that of free hFGF2 freeze-dried powder into the skin. At the same time, CLD can change the structure and content of lipids and keratin to increase the permeability of hFGF2 freeze-dried powder in skin tissue. Unlike the free state of hFGF2, the biophysical properties of single cells, including height and adhesion force, were changed under CLD-hFGF2 freeze-dried powder treatment. Meanwhile, CLD-hFGF2 freeze-dried powder was more easily taken up through keratinocytes without damaging cell integrity, which provided a new viewpoint for understanding the absorption mechanism with the CLD system for cellular physiology characteristics. Overall, our findings demonstrated that CLD could break through the stratum corneum (SC) barrier and elucidated the transport mechanism of lipid droplets in skin tissue, which provides a crucial guideline in drug delivery applications for future engineering. Full article
(This article belongs to the Special Issue Biodegradable Polymeric Nanosystems for Drug Delivery)
►▼ Show Figures

Graphical abstract

13 pages, 2659 KiB  
Article
Intracellular Drug Delivery Process of Am80-Encapsulated Lipid Nanoparticles Aiming for Alveolar Regeneration
by Tomomi Akita, Kazuaki Oda, Satoru Narukawa, Yuki Morita, Kota Tange, Yuta Nakai and Chikamasa Yamashita
Pharmaceuticals 2023, 16(6), 838; https://doi.org/10.3390/ph16060838 - 04 Jun 2023
Viewed by 1494
Abstract
Chronic obstructive pulmonary disease (COPD) results in obstructive ventilatory impairment caused by emphysema, and current treatment is limited to symptomatic therapy or lung transplantation. Therefore, the development of new treatments to repair alveolar destruction is especially urgent. Our previous study revealed that 1.0 [...] Read more.
Chronic obstructive pulmonary disease (COPD) results in obstructive ventilatory impairment caused by emphysema, and current treatment is limited to symptomatic therapy or lung transplantation. Therefore, the development of new treatments to repair alveolar destruction is especially urgent. Our previous study revealed that 1.0 mg/kg of synthetic retinoid Am80 had a repair effect on collapsed alveoli in a mouse model of elastase-induced emphysema. From these results, however, the clinical dose calculated in accordance with FDA guidance is estimated to be 5.0 mg/60 kg, and it is desirable to further reduce the dose to allow the formulation of a powder inhaler for clinical application. To efficiently deliver Am80 to the retinoic acid receptor in the cell nucleus, which is the site of action, we focused on SS-cleavable proton-activated lipid-like material O-Phentyl-P4C2COATSOME®SS-OP, hereinafter referred to as “SS-OP”). In this study, we investigated the cellular uptake and intracellular drug delivery process of Am80-encapsulated SS-OP nanoparticles to elucidate the mechanism of Am80 by nanoparticulation. Am80-encapsulated SS-OP nanoparticles were taken up into the cells via ApoE, and then Am80 was efficiently delivered into the nucleus via RARα. These results indicated the usefulness of SS-OP nanoparticles as drug delivery system carriers of Am80 for COPD treatment. Full article
(This article belongs to the Special Issue Biodegradable Polymeric Nanosystems for Drug Delivery)
►▼ Show Figures

Figure 1

12 pages, 11251 KiB  
Article
Tumor Microenvironment Responsive Nanomicelle with Folic Acid Modification Co-Delivery of Doxorubicin/Shikonin for Triple Negative Breast Cancer Treatment
by Wu Zhong, Zhehao Shen, Menglan Wang, Hongyi Wang, Yuting Sun, Xiaojun Tao and Defu Hou
Pharmaceuticals 2023, 16(3), 374; https://doi.org/10.3390/ph16030374 - 01 Mar 2023
Cited by 2 | Viewed by 1478
Abstract
Triple negative breast cancer (TNBC), which has poor prognosis, easily develops drug resistance and metastasizes. In general, those TNBC characteristics are related to a high activation of the epithelial-mesenchymal transition (EMT) pathway, which is inhibited by shikonin (SKN). Therefore, the synergistic therapy of [...] Read more.
Triple negative breast cancer (TNBC), which has poor prognosis, easily develops drug resistance and metastasizes. In general, those TNBC characteristics are related to a high activation of the epithelial-mesenchymal transition (EMT) pathway, which is inhibited by shikonin (SKN). Therefore, the synergistic therapy of SKN and doxorubicin (DOX) will increase anti-tumor efficacy and reduce metastasis. In this study, we prepared the folic acid-linked PEG nanomicelle (NM) grafted with the DOX (denoted as FPD) to load the SKN. We prepared the SKN@FPD NM according to the effective ratio of dual drugs, where the drug loadings of DOX and SKN were 8.86 ± 0.21% and 9.43 ± 0.13%, with 121.8 ± 1.1 nm of its hydrodynamic dimension and 6.33 ± 0.16 mV of zeta potential, respectively. The nanomaterials significantly slowed down the release of DOX and SKN over 48 h, leading to the release of pH-responsive drugs. Meanwhile, the prepared NM inhibited the activity of MBA-MD-231 cells in vitro. Further in vitro study revealed that the SKN@FPD NM increased the DOX uptake and significantly reduced the metastasis of MBA-MD-231 cells. Overall, these active-targeting NMs improved the tumor-targeting of small molecular drugs and effectively treated TNBC. Full article
(This article belongs to the Special Issue Biodegradable Polymeric Nanosystems for Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop